<i>In vivo</i> biocompatibility of ZIF-8 for slow release <i>via</i> intranasal administration
Sneha Kumari, Thomas S. Howlett, Ryanne N. Ehrman, Shailendra Koirala, Orikeda Trashi, Ikeda Trashi, Yalini H. Wijesundara, Jeremiah J. Gassensmith
Abstract
Zeolitic imidazolate framework-8 (ZIF-8) is becoming popular in research for its potential in antigen protection and for providing a thermally stable, slow-release platform. While papers applying this material for immunological applications are aplenty in the literature, studies that explore the biosafety of ZIF-8 in mammals-especially when administered intranasally-are not well represented. We checked the body clearance of uncoated and ZIF-8-coated liposomes and observed that the release slowed as ZIF-8 is easily degraded by mucosal fluid in the nasal cavity. We delivered varying doses of ZIF-8, checked its short- and long-term effects on diagnostic proteins found in blood serum, and found no noticeable differences from the saline control group. We also studied their lung diffusing capacity and tissue morphology; neither showed significant changes in morphology or function.